Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients with platinum refractory germ cell tumors (GCT): A phase 1 study

被引：0
|
作者：
Albany, Costantine [1 ]
Hashemi, Neda S. [1 ]
Fang, Fang [2 ]
Lowder, James [3 ]
Einhorn, Lawrence [1 ]
Nephew, Kenneth [2 ]
机构：
[1] Indiana Univ, Indianapolis, IN 46204 USA
[2] Indiana Univ, Bloomington, IN USA
[3] Astex Pharmaceut Inc, Pleasanton, CA USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-1386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1386
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
    Garcia-Manero, Guillermo
    Roboz, Gail
    Walsh, Katherine
    Kantarjian, Hagop
    Ritchie, Ellen
    Kropf, Patricia
    O'Connell, Casey
    Tibes, Raoul
    Lunin, Scott
    Rosenblat, Todd
    Yee, Karen
    Stock, Wendy
    Griffiths, Elizabeth
    Mace, Joseph
    Podoltsev, Nikolai
    Berdeja, Jesus
    Jabbour, Elias
    Issa, Jean-Pierre J.
    Hao, Yong
    Keer, Harold N.
    Azab, Mohammad
    Savona, Michael R.
    LANCET HAEMATOLOGY, 2019, 6 (06): : E317 - E327
  • [32] Phase II study of disulfiram (D) and cisplatin (P) in refractory germ cell tumors (GCTs).
    Mego, Michal
    Svetlovska, Daniela
    Schmidtova, Silvia
    Kalavska, Katarina
    Obertova, Jana
    Palacka, Patrik
    De Angelis, Valentina
    Lesko, Peter
    Orszaghova, Zuzana
    Rejlekova, Katarina
    Reckova, Maria
    Sycova-Mila, Zuzana
    Mardiak, Jozef
    Chovanec, Michal
    Kucerova, Lucia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17013 - E17013
  • [33] A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study
    Maio, M.
    Covre, A.
    Coral, S.
    Amato, G.
    Taverna, P.
    Lowder, J.
    Azab, M.
    Giannarelli, D.
    Natali, P. G.
    Di Giacomo, A. M.
    ANNALS OF ONCOLOGY, 2015, 26 : 7 - 7
  • [34] A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 study.
    Di Giacomo, Anna Maria
    Covre, Alessia
    Taverna, Pietro
    Coral, Sandra
    Amato, Giovanni
    Keer, Harold N.
    Lowder, James N.
    Giannarelli, Diana
    Azab, Mohammad
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITH CISPLATIN-REFRACTORY GERM-CELL TUMORS
    PUC, HS
    BAJORIN, DF
    BOSL, GJ
    AMSTERDAM, A
    MOTZER, RJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (02) : 163 - 165
  • [36] PHASE-II TRIAL OF CARBOPLATIN IN PATIENTS WITH ADVANCED GERM-CELL TUMORS REFRACTORY TO CISPLATIN
    MOTZER, RJ
    BOSL, GJ
    TAUER, K
    GOLBEY, R
    CANCER TREATMENT REPORTS, 1987, 71 (02): : 197 - 198
  • [37] A Bayesian randomized phase II study of guadecitabine (SGI-110) based regimens comparing guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + idarubicin (SGI5+Ida), 5 days + cladribine (SGI5+Clad), in untreated patients ≥ 70 years with acute myeloid leukemia (AML).
    Naqvi, Kiran
    Nogueras-Gonzalez, Graciela M.
    Cheung, Cora M.
    Pemmaraju, Naveen
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Dinardo, Courtney Denton
    Ohanian, Maro
    Jain, Nitin
    Takahashi, Koichi
    Alvarado, Yesid
    Konopleva, Marina
    Huang, Xuelin
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] A phase II single arm multi-center trial evaluating the efficacy of pembrolizumab in the treatment of patients (pts) with incurable platinum refractory germ cell tumors (GCT)
    Adra, Nabil
    Ammakkanavar, Natraj
    Radovich, Milan
    Vaughn, David J.
    Albany, Costantine
    Einhorn, Lawrence H.
    Hanna, Nasser H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia(r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies
    Daver, Naval
    Kantarjian, Hagop M.
    Roboz, Gail J.
    Kropf, Patricia L.
    Yee, Karen W. L.
    O'Connell, Casey L.
    Griffiths, Elizabeth A.
    Jabbour, Elias J.
    Stock, Wendy
    Walsh, Katherine J.
    Rizzieri, David A.
    Berdeja, Jesus G.
    Su, Xiang Yao
    Azab, Mohammad
    Issa, Jean-Pierre
    BLOOD, 2016, 128 (22)
  • [40] A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/ refractory germ cell tumors (GCT)
    Funt, Samuel A.
    Knezevic, Andrea
    Freeman, Benjamin A.
    Bolos, Mary
    Martorana, Victoria
    Donoghue, Mark
    Khan, Shah
    Singh, Harleen
    Bromberg, Maria
    Quinlan, Colleen
    Carousso, Maryann
    Jungbluth, Achim A.
    Patil, Sujata
    Shah, Neil J.
    Lee, Chung-Han
    McHugh, Deaglan Joseph
    Al-Ahmadie, Hikmat A.
    Feldman, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345